As a physician who had osteopathic training, I was frankly skeptical. However, my friend was very persuasive and we included this group of HCPs. In doing this, I believe, many of us who had not had professional exposure to chiropractors developed a strong appreciation for the skills they had to offer. After this realization, I would routinely call these individuals, now friends, and ask their advice, on occasion even taking x-rays to their offi ces for review. Furthermore, the membership was completely open; if you were an HCP and had an interest in or treated pain patients, you were welcome. In addition, the IPI had a strong representation of psychologists who specialized in chronic pain patients. It became quickly apparent to me and others in the group that this resource was underutilized and necessary in the treatment of pain. Because of this realization and the utilization by club members, one group had to hire another full-time psychologist to keep up with the referrals. Medical, nursing and pharmacy students found the IPI very instructive. They would routinely attend, and those students who rotated through my clinic as part of their medical school training were required to present a short article review to the group. This would usually occur before the main presentation of the evening. These were always well done and educational for all in attendance, as well as being very good experience for the students involved. Furthermore, it gave the students an appreciation for the complexities involved in the treatment of chronic pain, as well as the professionalism and desire for quality care that existed amongst those in our group.
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The success of this group is quite remarkable. There are rare multidisciplinary groups who meet regularly in any area of medicine but especially whose focus is on the treatment of pain. Furthermore, the evenings were opportunities for networking and discussing different approaches to a pain trigger's treatment.
A major part of the success of this group was due to the fi nancial support of the pharmaceutical industry. Unfortunately, the IPI was dissolved in 2010, almost 8 years to the day of its inception, the victim of misguided and arrogant notions of "confl ict of interest." Then came the PHARMA code and FDA oversight and one of the few multidisciplinary educational opportunities that occurred locally and on a monthly basis was gone forever.
The current notion of confl ict of interest manifested in the PHARMA code and FDA requirements is a juggernaut based on political philosophies rather than good, quality evidence and is seemingly unstoppable. Unfortunately, there are casualties that have occurred because of this political juggernaut, and the IPI demise is one such example. There are no multidisciplinary pain clinics in the state of Iowa; organizations like the IPI fulfi lled a tremendous need, the only potential for such a multidisciplinary interaction in the state and one of few nationwide. A format for multidisciplinary interactions, discussions, case studies and education in the treatment of pain in the state of Iowa does not currently exist. Although one could argue that committed professionals should attend such things and pay their own way, without sponsorship the reality belies such thoughts. Furthermore, many of those who attended were not wealthy or highly paid. Physical therapist, psychologist, nurses, students and many others were able to attend because of the industry sponsorship. In addition, the pragmatics of organizing meetings monthly for such a large attendance is very diffi cult to attempt without regular sponsorship. The government and academics are happy to make pronouncements of what we should not do and what we should think, but were certainly not forthcoming in funds to continue activities such as those illustrated by IPI. Sadly, IPI was allowed to die without comment from those in the hallowed halls of academia and government. Nervous System Advisory Committee. At that meeting, according to the email, "the Committee will discuss a new imaging agent to be used in the assessment of dopaminergic neuron function," and I was asked, "to speak on the topic of differential diagnosis of patients with movement disorders and the role of neuroimaging in the evaluation of these patients." I had more than enough work to do, but this sounded like an intriguing opportunity. After all, I have more than 25 years experience with neuroimaging research in Parkinson disease and related conditions, with particular expertise in imaging dopaminergic pathways in the brain. I have had multiple grants from the National Institutes of Health supporting my neuroimaging research. One of these grants, entitled "Validation of Neuroimaging Biomarkers of Nigrostriatal Neurons," is precisely designed to develop and validate neuroimaging biomarkers of dopaminergic pathways-which include nigrostriatal neuronsa major component of dopamergic pathways. Of course, it may be relevant to disclose that I originally proposed this grant since I was rather concerned that multiple national and international studies had applied neuroimaging measures of dopaminergic pathways as endpoints of clinical research studies without having, at least in my mind, adequate validation of the methods (Ravina et al., 2005) . I have been a rather hard-nosed person with regard to what constitutes adequate validation. The other part of my background that is relevant to disclose is that I am head of the Movement Disorders Center at Washington University in St. Louis. In that role, I am responsible for a large clinical, teaching and research operation that focuses on Parkinson and related diseases. I have always been a rather serious clinical-educator, constantly grilling medical students, neurology residents and movement disorders fellows on how any test that they order for a patient helps with decision-making for that patient. "If the test results will not alter decisionmaking, then do not order it," many trainees have heard me emphasize. Given this background and my Missouri upbringing (the Show Me state), I thought it was reasonable to respond affi rmatively to this invitation. After all, this would be my chance to provide a non-industry perspective and clearly state my position on the topic at hand. And, my position was clear-I do not believe that current evidence justifi es the clinical application of molecular neuroimaging of dopaminergic systems in the brain.
Expert
Let me fi rst give you some background on the potential clinical relevance of measuring dopaminergic pathways in the brain. Abnormalities of dopaminergic pathways in the brain underlie several neurologic and psychiatric illnesses and may also be critically important to treatment of those conditions. The most straightforward example is idiopathic Parkinson's Disease (PD), a disease that primarily affects older individuals that causes progressive diffi culty with walking, stiffness, slow movement, poor balance, tremor, soft speech and trouble swallowing. Many people also develop cognitive impairment. Destruction of these dopaminergic neurons in the brain leads to many of these manifestations. Notably, any other cause that reduces function of these neurons, like drugs that block dopamine action, may produce similar symptoms. The current gold standard for diagnosis of idiopathic PD is examination of the brain after one dies, and this permits identifi cation of the loss of dopaminergic neurons and abnormal deposition of a protein called alpha-synuclein. Other related diseases like multiple systems atrophy, progressive supranuclear palsy or cortical basal ganglia syndrome may cause similar symptoms but may progress more quickly than Parkinson disease and respond less well to medications that can provide symptomatic relief to those with idiopathic PD. People with idiopathic PD also may develop cognitive impairment leading to dementia. The dementia may be caused by underlying abnormal deposition of alpha-synuclein in higher brain regions (socalled synucleinopathy) but also could be caused by pathologic changes similar to those that occur in Alzheimer's disease. In fact, those who develop dementia may have Alzheimer's disease as a cause or an alpha-synucleinopathy with defects in dopaminergic pathways.
The next relevant point is how dopaminergic pathways are measured in the brain in living humans or animals. A variety of molecular imaging methods have been developed for this. Basically, each of these requires a radiolabeled chemical that is injected intravenously into a person and the radiotracer then enters the brain to more or less selectively stick to some part of a dopaminergic neuron or gets trapped in the brain by some mechanism related to the integrity of dopaminergic neurons. The goal of such scans is to measure the number or function of these neurons. Some tracers require imaging with positron emission tomography (PET)-relatively expensive but with higher resolution-or with single photon emission computed tomography (SPECT)-lower resolution and less expensive. A fair amount of work has demonstrated that these methods all can distinguish with varying sensitivity a person with PD from a normal subject.
This background information provides the basis for determining what may be the clinical utility of measuring dopaminergic pathways in the brain. Could such measures help with the diagnosis of PD by confi rming a defect in the dopaminergic pathways that occurs in PD but perhaps not in some other conditions-like someone with essential tremor-a condition that causes tremor that at times is diffi cult to distinguish from PD? If so, would this improve patient care? In other words, could we avoid giving someone medicine for PD who is not likely to benefi t from it (Stoessl, 2009) ? Could the measures help provide prognostic information for individual patients and predict the rate of disease progression? Could such measures help identify those who have dementia due to alphasynucleinopathy rather than Alzheimer's disease? (McKeith et al., 2007) Can these techniques identify a person at risk for developing PD? Substantial controversy exists as to whether these methods can answer these questions (Serrano Vicente et al., 2009; Eerola et al., 2005) . Many national and international meetings (like the International Movement Disorders Society) have forums for addressing these controversies. In fact, some of these methods have been approved for clinical application in other countries. None had been approved by the FDA for clinical application in this country. So, this invitation was my opportunity to review the research data that I believe demonstrate no clinical utility at the current time for these molecular neuroimaging methods. After a review of the literature I did not believe that the methods helped with diagnosis of PD-the data do not support the notion that it can distinguish PD from related conditions. Some believe that less closely related conditions like essential tremor can be distinguished (Eerola et al., 2005; Ceravolo et al., 2008) but I argued that if there was clinical ambiguity that obscured confi dent clinical diagnosis between these two conditions in an individual, then a simple trial of treatment for PD would be a more direct and far less expensive alternative to a molecular imaging test. Similarly, the only data that supported such techniques to help distinguish causes of dementia were funded by industry that made these types of radiotracers (McKeith et al., 2007) , an arrangement that may bias reporting only positive outcomes (Kelly, Jr. et al., 2006) . In contrast, I do believe that molecular imaging of dopaminergic pathways may be a more sensitive means to identify a defect in these neurons before it can be detected clinically by an appropriately trained neurologist (Marek & Jennings, 2009 )-however, today we have no treatment that can prevent or slow disease progression to make this a useful clinical tool. In the future, we may have such preventative treatments and then, with appropriate selection criteria, these types of scans may help identify and treat people to prevent onset of PD symptoms.
So, I decided to participate in this advisory committee meeting. I was told that the agenda would include a basic review of Parkinson disease by Dr. Ted Dawson from Johns Hopkins University and then I would review the potential clinical utility of neuroimaging dopaminergic pathways in movement disorders. After that there would be presentations by the FDA, presentations by industry and then panel discussion and committee questions.
Everyone arrived at the meeting on time in Silver Spring, Maryland. Dr. Dawson gave an excellent review of Neurodegeneration in PD and then I reviewed the literature on "Neuroimaging of Dopaminergic Neurons: Evidence for Clinical Utility." In my talk, I also addressed the cost effectiveness of applying molecular imaging for diagnosis compared to a trial of drug-this favored a simple short testing of the response to a drug by a 10-to-1 cost differential. My fi nal slide, entitled "Clinical Utility?" included the bullet points that these techniques were not needed for clinical utility and not necessary for treatment decisions in patients. My conclusions were straightforward.
What then happened? Dr. Dawson and I were invited to observe the remaining talks and sit in the public audience area. We were told that we could not participate in any discussions or ask any questions. The FDA had speakers and GE Healthcare had several speakers justifying their proposal for clinical application of a SPECT radiotracer to measure dopaminergic neurons. We could observe the FDA panel members ask questions of other speakers but we were not allowed to ask or answer questions from the panel or anyone else at that point. Once we sat down after giving our talks, we were prohibited from participation. I must say, I was quite surprised. This permitted several misperceptions to go unanswered. For example, one FDA panel member specifi cally stated that Dr. Perlmutter supports this clinical application-quite far from my position, but I was not allowed to clarify that point. One of the GE Healthcare representatives presented data from a study that they had sponsored with the conclusion that it was clinically useful to use one of their molecular imaging markers to properly diagnose dementia due to synucleinopathy-a position that I do not endorse. There were multiple questions by panel members that we could have easily addressed but again we were not allowed to respond and they were not permitted to address us. One panel member specifi cally asked the chair of the panel whether they could consider cost effectiveness of this drug and was told that was not to be considered in their decision to recommend or not recommend approval of the application from GE Healthcare.
I left that meeting feeling that I was window dressing rather than a considered expert on an important topic. The next week, I learned that the panel voted 11-to-2 to recommend approval of the GE Healthcare application.
What are the ethical issues raised by this experience? First, I am concerned that there was a lack of interaction between the committee and the invited experts. The playing fi eld was not level. How come? The challenges to the FDA are substantial. There are pressures to approve new drugs that can improve health care for Americans. Frequent complaints arise from the public about delays with FDA approval. Yet, we also hear about potential bias from FDA panel members that may have relationships to industry and that the FDA receives a substantial part of its funding from industry sources-the same industry that the FDA regulates (Olsen & Whalen, 2009 ). These confl icts of interest exist (Kelly, Jr. et al., 2006) . I believe that my experience demonstrates one example of where potential bias of information can infl uence a panel. In fairness, there are many other movement disorders specialists who believe that these imaging methods would help them make decisions. One such movement disorders specialist also gave a presentation for GE Healthcare at the meeting and made the point that neurologists in other countries can order these molecular imaging tests and we cannot-a defi ciency that he thought should be corrected. However, my position is that when the FDA considers such applications, a more thorough and objective review of the data is warranted. The question really is "who wants the truth?"
Crossroads: The Intersection of Personal, Professional Society, and Industry Relationships William H. Seitz, Jr. and Edward Diao B eing hand surgeons who have been researchers, educators and clinicians, responsible for the education of medical students, residents, fellows and peers, who by necessity have worked with industry to develop new products, for which we have been compensated, we have always represented our involvement and potential confl icts in all of our professional activities. As such, we have been tapped over the past ten years by The American Society for Surgery of the Hand (ASSH) to develop and expand its relationships with industry to support our mission of education, research and innovation. This work was begun long before the investigation by the Department of Justice of improper personal relationships between orthopedists and industry.
We helped provide a peer-reviewed process for education and display of industry's new technology at our annual meetings, which fi nancially fueled our ability to enhance the quality of the meetings. This included the development of "hands-on" skilled workshops where industry provides surgeons opportunity to physically utilize new technology in a simulated surgical environment. The industry participants were charged a fee for this opportunities, and very quickly these opportunities became highly sought after by industry and signifi cant revenues were generated. This provided feedback for industry from the surgeon participants to improve their equipment and, at the same time, it provided surgeons with access in a single venue to become familiar with new technology. In turn, the revenues generated provided fi nancial support to reduce the overall cost of the annual meeting to our membership. Additionally, the development of this partnership with industry lead to interest in industry providing support for education and research as well as educational grants to allow more young surgeons to attend the annual meeting. Last year industry supported fi fty $1,500.00 scholarships for residents and fellows as well as armed forces surgeons to attend our annual meeting.
Thus began the formation of relationships of "no-strings-attached" philanthropy by industry to promote meaningful research, which has itself helped direct industry to pursue new frontiers of product development. For the past three years our industry partners have contributed substantially to increase the amount of available funds in our
